Akebia Therapeutics, Inc.
AKBA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.74 | -10.02 | -0.15 | -0.92 |
| FCF Yield | 3.91% | 2.32% | -3.01% | -1.08% |
| EV / EBITDA | 123.73 | 117.86 | 27.68 | -62.49 |
| Quality | ||||
| ROIC | 0.78% | 6.06% | 6.02% | -9.86% |
| Gross Margin | 84.03% | 84.12% | 86.70% | 56.20% |
| Cash Conversion Ratio | 52.05 | 90.47 | -2.22 | 0.20 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.15% | 0.57% | -11.88% | -18.14% |
| Free Cash Flow Growth | 27.14% | 263.31% | -204.50% | 32.97% |
| Safety | ||||
| Net Debt / EBITDA | 7.53 | -11.35 | -4.17 | 0.64 |
| Interest Coverage | 0.94 | 2.06 | 1.74 | -2.08 |
| Efficiency | ||||
| Inventory Turnover | 0.50 | 0.59 | 0.39 | 1.25 |
| Cash Conversion Cycle | 183.49 | 151.66 | 180.09 | 71.22 |